Róisín Shortall (Dublin North West, Social Democrats)
Link to this: Individually | In context | Oireachtas source

1290. To ask the Minister for Health the reason generic manufacturers are not involved in negotiations on medicines pricing agreements; if he will give consideration to drafting a national medicines strategy in order to achieve greater cost effectiveness for the State and consumers; and if he will make a statement on the matter. [38997/17]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The scope of the Framework Agreement on the Supply and Pricing of Medicines (IPHA Agreement) is defined as applying to any patent protected medicinal product and any off-patent medicinal products which have not been declared interchangeable by the HPRA. The price of generic and interchangeable medicines are set by reference to the Health (Pricing and Supply of Medical Goods) Act 2013.

Ensuring the rational and cost effective use of medicine is a key priority and my officials are currently examining a range of policy options in this area. The drafting of a national medicines strategy, as referenced by the Deputy, will be considered as part of this process.

Engagement and consultation with all stakeholders, including manufacturers, will form a key part of this work.